People
Frank Reynolds, the founder and chief executive officer of PixarBio, was also ordered to repay $7.5 million to investors who backed the company’s non-opioid painkiller, NeuroRelease.
Dr. Bopp is a pioneer in understanding the impact of the acidic tumour microenvironment on local immune cell function
World-leading scientists and clinicians steer Silence’s ground-breaking siRNA research programme into disease areas with high unmet medical need
Although the concept of genome editing is just starting to gain traction, it has the potential to revolutionize health care by being able to treat, and in many cases cure, previously difficult-to-treat or untreatable genetic diseases. Intellia Therapeutics is focused on implementing a full-spectrum genome editing approach.
The company will be helmed by Jes Olesen, the former president of the European Federation of Neurological Societies and chairman of the Danish Headache Center.
The trial’s goal is to test more than 700 patients infected with the coronavirus, but at this point, there have been fewer than 200 people recruited.
The U.S. Food and Drug Administration’s Office of Prescription Drug Promotion is interested in how social media affects the public’s perception of drugs.
Biopharma and life sciences companies bolster their leadership teams and board with this week’s Movers & Shakers.
The outbreak of the coronavirus, now called COVID-19, is taking some unexpected twists and turns.
The company’s efforts appear to be working, as it reported fourth-quarter results that exceeded expectations. Company shares popped 9.1% at the news.
PRESS RELEASES